Literature DB >> 23526408

'Elderly' patients with newly diagnosed glioblastoma deserve optimal care.

Matthias Holdhoff, Gary L Rosner, Sara Alcorn, Stuart A Grossman.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23526408      PMCID： PMC4086527          DOI： 10.1007/s11060-013-1113-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  6 in total

Review 1.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

2.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

Review 3.  Treatment of glioblastoma in "elderly" patients.

Authors:  Susannah Yovino; Stuart A Grossman
Journal:  Curr Treat Options Oncol       Date:  2011-09

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Authors:  Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller
Journal:  Lancet Oncol       Date:  2012-05-10       Impact factor: 41.316
  6 in total
  3 in total

Review 1.  Management of elderly patients with gliomas.

Authors:  Jaime Gállego Pérez-Larraya; Jean-Yves Delattre
Journal:  Oncologist       Date:  2014-10-23

2.  Outcomes in newly diagnosed elderly glioblastoma patients after concomitant temozolomide administration and hypofractionated radiotherapy.

Authors:  Ludovic T Nguyen; Socheat Touch; Hélène Nehme-Schuster; Delphine Antoni; Sokha Eav; Jean-Baptiste Clavier; Nicolas Bauer; Céline Vigneron; Roland Schott; Pierre Kehrli; Georges Noël
Journal:  Cancers (Basel)       Date:  2013-09-24       Impact factor: 6.639

3.  The future of high-grade glioma: Where we are and where are we going.

Authors:  Emilie Le Rhun; Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2015-02-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.